Psoriasis vulgaris. Plaque psoriasis
Conditions
Interventions
Intervention 1: Use of vehicle 2 times per day on all plaques for 12 continuous weeks. Intervention 2: Use of calcipoteriol cream 50mg/g 2 times per day on all plaques for 12 continuous weeks. Interve
Placebo
Treatment - Drugs
Use of vehicle 2 times per day on all plaques for 12 continuous weeks
Use of calcipoteriol cream 50mg/g 2 times per day on all plaques for 12 continuous weeks
Use of Alnovat Cream 2 times per day on all plaques for 12 continuous weeks
Sponsors
ALNAPHARM GmbH & Co.KG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion/Exclusion: Diagnosed plaque-psoriasis with a body surface affected less than 10%;Treatment naive with either topical and/or systemic medications and/or phototherapy in last 4 weeks before enrolment in the study; No background of taking medicines which are known to potentially trigger psoriasis including beta blockers, lithium and antimalarial drugs; Willing to participate in the study considering the visit requirements; Able to read, understand and sign patient informed consent.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI score. Timepoint: Baseline,weeks2,4,8,12. Method of measurement: Inspection. | — |
Secondary
| Measure | Time frame |
|---|---|
| Added at 2015-04-19: 1-Number of Patients who reached PASI 75 and PASI 50 at any time during the study. or 2-Adverse events of Alnovat during topical administration in adult patients with mild plaque psoriasis. Timepoint: Added at 2015-04-19: at any time during the study. Method of measurement: Added at 2015-04-19: PASI Score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Parvin Mansouri
Tehran Univeristy of Medical Science
Outcome results
None listed